HIV and AIDS Research News & Events
Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
News
This year marks the 50th Anniversary of the United States National Cancer Act and NCI is commemorating this landmark legislation. As a result of this investment in cancer research, by the 1980s NCI was in a strong position to make advances in the fight against HIV/AIDS.
August 2021
Although many doubted whether any drug could be developed to fight AIDS, Dr. Robert Yarchoan worked with Drs. Samuel Broder and Hiroaki Mitsuya on the first AIDS drugs, including azidothymidine (AZT), transforming a fatal disease into a chronic one.
August 2021
The National Institutes of Health Office of AIDS Research (OAR) joins colleagues worldwide to commemorate to 40th anniversary of the landmark 1981 Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) that first recognized the syndrome of diseases as later named AIDS. Below are two MMWR relevant articles.
June 2021
Learn how the AIDS and Cancer Specimen Resource (ACSR) developed new strategies to improve visibility by using a cross disciplinary approach.
Biopreservation and Biobanking
May 2021
In celebration of World AIDS Day 2020, Dr. Robert Yarchoan provided a reflection on the history of HIV drugs developed at NCI, on HIV malignancies, and how HIV research is informing research on drugs against COVID.
December 2020
Researchers in the HIV and AIDS Malignancy Branch, CCR reported trial results showing that treatment of aggressive HIV-associated primary central nervous lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate is associated with high response rate, CD4+ lymphocyte reconstitution, and long-term survival with preservation or improvement of neurocognitive function.
Blood
July 2020
On May 14, 2020 FDA approves pomalidomide for AIDSrelated Kaposi sarcoma. The approval of Pomalyst was as a result of a Phase 1/2 clinical trial in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma conducted by a team led by Dr. Robert Yarchoan of the HIV and AIDS Malignancy Branch.
Results from a large clinical trial supported by NCI and NIAID demonstrated that patients with advanced AIDS-associated Kaposi sarcoma have
improved outcomes when treated with antiretroviral therapy and the chemotherapy drug paclitaxel.
Lancet
March 2020
The NIH Record highlighted the 25th Anniversary of Kaposi sarcoma-associated herpesvirus (KSHV) which was celebrated at the 17th International Conference on Malignancies in HIV/AIDS. At the meeting Dr. Douglas Lowy, then acting director of NCI, presented the NCI Director's award to Drs. Patrick Moore and Yuan Chang for their discovery two of the known oncogenic viruses (KSHV and Merkel cell polyomavirus) and their research to elucidate the biology of these viruses.
October 2019
Read about Dr. Robert Yarchoan and the Office of HIV and AIDS Malignancy. This article highlights OHAM's efforts in HIV/AIDS malignancy research.
POZ
July 2019
Researchers from NCI and the Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab.
JAMA Oncology
June 2019
Researchers from the AIDS Malignancy Consortium have completed a cervical cancer trial in sub-Saharan Africa showing that women living with HIV can be treated with concomitant chemoradiotherapy using the same dose as HIV-negative women.
Gynecologic Oncology
April 2019
Researchers at NCI have demonstrated that cytokine dysregulation is a hallmark of primary effusion lymphoma pathogenesis, symptom profile and natural history.
Blood
February 2019
The latest information on the epidemiological, clinical features and treatment options for Kaposi sarcoma is highlighted in this review.
Nature Reviews Disease Primers
January 2019
Events
KSHV Vaccine Workshop
October 13, 2021, 10:00 AM-5 PM EST
WebEx Event
The workshop participants will discuss the need, potential, and feasibility of developing a KSHV vaccine that will prevent initial infection or development of disease, not a therapeutic vaccine.
If you have any questions contact Geraldina Dominguez (domingug@mail.nih.gov).
Below is the WebEx information to access the workshop. https://cbiit.webex.com/cbiit/j.php?MTID=m64431d859831e3af8002eca5d56140e4 Wednesday, Oct 13, 2021 9:30 am | 8 hours | (UTC-04:00) Eastern Time (US & Canada) Event number: 2302 823 8380 Event password: ZMqc32GsP@7 (96723247 from phones) Join by phone 1-650-479-3207 Call-in toll number (US/Canada) Access code: 230 282 38380